Clinical impacts of histological subtyping primary breast cancer

Anticancer Research

Volumn 30, Issue 12, 2010, Pages 5137-5144

  Fritz, P ^a,e   Klenk, S ^a   Goletz, S ^a   Gerteis, A ^b   Simon, W ^b   Brinkmann, F ^d   Heidemann, E ^d   Lutttgen E ^b   Ott, G ^a,b   Alscher, M D ^a   Schwab, M ^e   Dippon, J ^c  

^a Institute of Digital Medicine   (Germany)

^b ROBERT BOSCH HOSPITAL   (Germany)

^c UNIVERSITY OF STUTTGART   (Germany)

^d Onkologischer Schwerpunkt   (Germany)

^e DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

Breast cancer; Histology; Steroid receptors; Survival analysis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER GRADING; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INVASIVE DUCTAL BREAST CARCINOMA; INVASIVE LOBULAR BREAST CARCINOMA; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE RISK; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 78751471037     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Tavassoli FA, Devilee P: World Health Organization Classifications of Tumors and Genetics. Tumors of the Breast and Female Genital Organs. Lyon, IARC Press, 2003.
2. TNM Klassifikation maligner Tumoren. Sechste Auflage. UICC. Wiley Blackwell.
3. Sloane JP, Amendoeira I, Apostolikas N, Bellocp JP, Bianchi S, Boecker W, Bussolati G, Coleman D, Connolly CE, Eusebi V, de Miguel C, Dervan P, Drijkoningen R, Eiston CW, Faverly D, Grad A, Jacquemir J, Lacerda M, Martinez-Penuela J, Munt C, Peterse JL, Rank F, Sylvan M, Tsakraklides V and Zafrani B: Consistency achieved by 23 European pathologists from 12 countries in diagnosing breast disease and reproting prognostic features of carcinomas. European Commission Working Group on Breast Screening Pathology. Virchows Arch 434: 3-10, 1999.
4. Onkologischer Schwerpunkt Stuttgart, www.osp-stuttgart.de/Startseite.htm
5. Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection(ER-ICA) in breast cancer tissue. Pathologe 8: 138-140, 1987.
6. Dippon J, Fritz P and Kohler M: A statstical approach to case based reasoning with application to breast cancer data. Comput Statist Data Anal 40: 579-602, 2002.
7. Klenk S, Dippon J, Fritz P and Heidemann G: Interactive survival analysis with the OCDM system: from development to application. Issue of Knowledge Discovery and Management in Biomedical Information Systems with the Journal of Information Systems, Springer 2009. Inf Syst Front 11: 391-403, 2009.
8. Bornhak S, Heidemann E, Herschlein HJ, Simon W, Merkle E, Widmaier G, Ernst R, Greulich M, Bittner R, Kieninger G, Merkle P, Strosche H, Karg C, Wellhauesser U, Aulitzky W, Schmidt B, Metzger H, Hahn H, Stauch A, Meisner C, Selbmann HK, Regelmann C and Brinckmann F: Symptom-oriented follow-up of early breast cancer is not inferior to conventional control. Results of a prospective multicenter study. Onkologie 30: 443-449, 2007.
9. R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-90061-07-0, 2008. URL http://www.R-project.org
10. Fitzgibbons PL, Connolly JL and Page DL: Updated protocol for the examination of specimens from patients with carcinomas of the breast. Arch Pathol Lab Med 124: 1026-1033, 2000.
11. Nationale S3 Richtlinie: Diagnostik, Therapie und Nachsorge des Mammakarzinoms der Frau- Interdisziplinäre Leitlinie der Deutschen Krebsgesellschaft und der beteiligten medizinischwissenschaftlichen Fachgesellschaften. Deutsche Krebssgesellschaft e.V. Version Juli 2004.
12. Henson DE and Ries L: On the estimation of survival. Semin Surg Oncol 10: 2-6, 1994.
13. Henson DE, Ries LA and Carriaga MT: Conditional survival of 56268 patients with breast cancer. Cancer 15: 237-242, 1995.
14. Henson DE, Chu KC and Levine PH: Histological grade, stage and survival in breast carcinoma: comparsion of African American and Caucasian women. Cancer 95: 908-917, 2003.
15. Qureshi HS, Linden MD, Divine G and Raju UB: E-Cadherin status in breast cancer correlates with histological type but does not correlate with established prognostic parameters. Am J Clin Pathol 125: 377-385, 2006.
16. Ellis IO, Galea M, Broughton N, Locker A, Blarney RW and Elston CW: Pathological prognostic factors in breast cancer II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology 20: 479-489, 1992.
17. Ellis IQ, Coleman D, Wells C, Kodikara S, Paish EM, Moss S, AlSam S, Anderson N, Bobrow L, Buley I, Connolly CE, Dallimoe NS, Hales S, Hanby A, Humphreys S, Knox F, Lowe J, Macartney J, Nash R, Parham D, Patrick J, Pinder SE, Quinn CM, Robertson AJ, Shrimankar J, Walker RA and Winder R: Impact of a national external quality assessment scheme for breast pathology in the UK. J Clin Pathol 59: 138-145, 2006.
18. Rejthar A and Nenutil R: The prognosis of ductal invasive breast carcinoma in histopathology. Cesk Pathol 32: 123-131, 1996.
19. Salazar EL, Calzado L and Pedro N: Infiltrating ductal/lobular carcinoma: an evaluation of prognostic factors in primary breast cancer. Arch AIDS Res 10: 73-82, 1996.
20. Toikkanen S, Pylkkänen L and Joensuu H: Invasive lobular carcinoma of the breast has a better short- and long-term survival than invasive ductal carcinoma. Br J Cancer 76: 1234-1240, 1997.
21. Du Toit RS, Locker AP, Ellis IO, Elston CW, Nicholson RI and Blamey RW: Invasive lobular carcinomas of the breast - the prognosis of histopathological subtypes. Br J Cancer 60: 605609, 1989.
22. Weiss MC, Fowble BL, Solin JL, Yeh IT and Schultz DJ: Outcome of conservative therapy for invasive breast cancer by histological subtype. Int J Rad Oncol Biol Phys 23: 941-947, 1992.
23. Sinha PS, Bendall S and Bates T: Does routine grading of invasive lobular cancer of the breast have the same prognostic significance as for ductal cancers? Eur J Surg Oncol 26: 733737, 2000.
24. Tot T: The diffuse type of invasive lobular carcinoma of the breast: morphology and prognosis. Virchows Arch 443: 718-724, 2003.
25. Li CI, Moe RE and Daling JR: Risk of mortality by histological type of breast cancer among women aged 50-79 years. Arch Intern Med 163: 2149-2153, 2003.
26. Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau SW, Broglio K, Therialut RL, Valero V, Buzdar AU, Kuerer H, Buccholz RA and Hortobagyi GN: Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 25: 41-48, 2005.
27. Cocquyt V and van Belle S: Lobular carcinoma in situ and invasive lobular cancer of the breast. Curr Opin Obstet Gynecol 17: 55-60, 2005.
28. Santiago RJ, Harris EE, Qin L, Hwang WT and Solin LJ: Similar long-term results of brest cancer conservation treatment for stage I and II invasive lobular carcinoma compared with invasive ductal carcinoma of the breast: the University of Pennsylvania experience. Cancer 103: 2447-2454, 2005.
29. Silverstein MJ, Lewinsky BS, Waismann JR, Gierson ED, Colburn WJ, Senofsky GM and Gamagami P: Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma? Cancer 75: 1673-1677, 1994.
30. Vo TN, Meric-Bernstam F, Buchholz TA, Ames FC, Kuerer HM, Bedrosian, I and Hunt KK: Outcomes of breast cancer conservation therapy for invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma. Am J Surg 192: 552-555, 2006.
31. Turashvili G, Bouchal J, Baumfarth K, Wei W, Dziechciarkova M, Ehrmann J, Klein J, fridman E, Škarda J, Srovnal J, Hajduch M, Murray P and Kolar Z: Novel markers for differentiation of lobular and ductal invasive breast cancer by laser microdissection and microarray analysis. BMC Cancer 7: 55-75, 2007.
32. Zhao H, Langerod A, Youngran J, Nowels KW, Nesland JM, Tibshirani R, Bukholm IK, Karesen R, Botstein D, Dale AL and Jeffrey SS: Different gene expression patterns in invasive and ductal carcinoma of the breast. Mol Biol Cell 15: 2523-2536, 2004.
33. Jirström K, Ryden L, Anagnostaki L, Nordenskjöid B, Stäl O, Thorstenson S, Chebil G, Jönsson PE, Fernö M and Landberg G: Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial. J Clin Pathol 11: 1135-1142, 2005
34. Jaremko M, Justenhoven C, Schroth W, Abraham BK, Fritz P, Vollmert C, Illig T, Simon W, Schwab M and Brauch H: Polymorphism of the DNA repair enzyme XRCC1 is associated with treatment prediction in anthracycline and cyclophosphamide/ methotrexate/5-fluorouraciI-based chemotherapy of patients with primary invasive breast cancer. Pharmacogenet Genomics 17: 529538, 2007.